Grifols was up to 4.6% on Tuesday on the stock market after 9:15 a.m., after publishing its first-quarter earnings for this year on Monday, with the market already closed, when it earned 60 million euros, almost triple (+179%) from the same period in 2024, surpassing its forecasts.
In this context, the ‘A’ class shares of the hemoderivatives company, those that are listed on the Ibex 35, rose by 4.62%, to 8.78 euros per share, while the ‘B’ type shares, traded on the Continuous Market, rose by 4.32%, to a unit price of 6.875 euros.
From its income statement, it is evident that the Catalan company increased its sales by 7.4%, to 1.786 billion euros, while its adjusted gross operating profit (Ebitda) stood at 400 million, 14.2% more than between January and March 2024, with a margin of 22.4%.
On the other hand, the Minority Shareholders of Grifols (AMG) have celebrated the results of the company’s first quarter, emphasizing that, «as expected,» these figures point to a «continuity of strong improvement in all business magnitudes.»
In this context, the company has reaffirmed its forecasts for the current fiscal year, which it already announced at its Capital Markets Day last February, aiming to record revenues of around 7.7 billion euros –excluding the U.S. Inflation Reduction Act (IRA)–, representing an increase of nearly 7% compared to the revenue recorded in 2024.
In its guidance for this year, also excluding the IRA, Grifols expects to record an adjusted Ebitda of around 2.025 billion euros, a 14% increase from the 1.779 billion euros obtained between January and December of last year.
Furthermore, the company plans to restore remuneration to its shareholders from 2025 and sees room for share buybacks within its strategic plan.
